Ultragenyx Pharma Loss Widens On Research Costs

(RTTNews) - Ultragenyx Pharmaceutical Inc (RARE), a clinical stage company focused on rare diseases, on Thursday reported second-quarter net loss to common stockholders of $29.8 million or $0.83 per share compared with a loss of $13.6 million or $0.45 per share last year.

Analysts polled by Thomson Reuters estimated a loss of $0.63 per share for the quarter. Analysts' estimates typically exclude special items.

Operating expenses for the quarter rose to $30.1 million from $13.7 million a year ago, reflecting clinical trial and other development expenses as well as general costs.